Adocia raises €3M equity in €7M package to extend runway to 2028
What's the deal? French biopharmaceutical company Adocia has raised a €7 million financing package, comprising a €3 million capital increase and a €4 million increase to its shareholder loan with Vester FinanceDealroom has a profile for this one. Try Dealroom →. The equity portion issued 1,477,934 new shares at €2.04 each, with participation from all of the company's directors, chief executive officer Olivier Soula, and a limited number of historical investors.
Why now? Adocia reported a cash position that funded operations only to early in the second quarter of 2027, and its 2026 half-year report flagged uncertainty over the company's ability to continue as a going concern. The financing, combined with cost reductions begun in September 2026, extends the cash runway to the first quarter of 2028 and removes that going-concern uncertainty.
What's the endgame? Adocia develops therapies for diabetes and obesity. The new money is a bridge to a $20 million milestone payment tied to Chinese marketing-authorization approval for its ultra-rapid insulin BioChaperone Lispro, developed with partner Tonghua Dongbao. If approved, the company projects its runway would extend to 2029.
What could go wrong? The milestone is not secured. Approval in China remains uncertain, and the extended runway assumes full use of the Vester Finance loan — whose cap rises from €6 million to €10 million — plus revenue from partnerships Adocia has yet to sign.
The proceeds will also fund promotion of Adocia's BioChaperone technology to attract partners and advance its AdoXLong peptide platform toward clinical development. "Our priority is to generate business revenues as quickly as possible and to use this shareholder loan only when appropriate," Soula said.
The signal: The deal follows a €10 million fundraising in December 2025 and the original Vester loan in April 2026, underscoring Adocia's repeated reliance on external financing in what Soula called a "challenging funding environment for the European biotechnology sector." It buys time, but the path to self-sustaining revenue still hinges on a single regulatory decision abroad.
Read more: finanznachrichten.de
Image credit: .:[ Melissa ]:.
